Almirall stock gains on Jefferies Buy rating and upside potential

Almirall stock (ISIN ES0157097017) is trading near EUR 10.62 on the Spanish Mercado Continuo on September 17, 2026, close to the lower end of its recent range and below the EUR 16.00 price target reiterated by Jefferies in mid-September 2026.

Jefferies reiterates Buy rating with 55 percent upside

According to Bolsamania on September 11, 2026, Jefferies has reiterated its Buy recommendation on Almirall with a price target of EUR 16.00 per share, which implies more than 55 percent upside versus levels around EUR 10.30 to EUR 10.40 at the time of the report.

The same report notes that Jefferies reaffirmed its positive view after a meeting with Almirall chief executive officer Carlos Gallardo Pique, the chief financial officer and the chief scientific officer, focusing on the acceleration of the dermatology drug Ebglyss and its potential to drive medium term growth.Bolsamania

Share price, 52-week range and market capitalization

Per data from a Spanish stock portal at 10:42 on September 17, 2026, Almirall stock stands at EUR 10.62 on the Spanish Mercado Continuo, down 0.56 percent on the day, with a drop of EUR 0.06 from the prior close of EUR 10.68, while the intraday trading range so far has been between EUR 10.60 and EUR 10.80.

The same price overview shows that Almirall shares trade in a 52-week range between EUR 10.02 and EUR 13.98, meaning the current price of EUR 10.62 is only slightly above the 52-week low and around 24 percent below the top of the range near EUR 13.98, underscoring the upside Jefferies sees versus both the historical high and its EUR 16.00 target.Bolsamania

Based on the same quote snapshot, Almirall’s market capitalization is around EUR 2,321.51 million as of September 17, 2026, giving the company mid cap status within the Spanish market and providing investors with a sense of scale as the dermatology portfolio expands.Bolsamania

Latest financials and Ebglyss growth prospects

In its most recent half year update for 2026, Almirall reported revenue and earnings figures that underpin Jefferies’ confidence, although the analyst house places particular emphasis on Ebglyss as a driver of acceleration rather than on short term topline growth.Almirall

According to the company’s investors section for the first half of 2026, Almirall pointed to continued investment in research and development and commercial rollout costs in dermatology, which weighed on margins but are expected to support medium term revenue growth as key products such as Ebglyss penetrate their target markets.Almirall

Risk factors and next catalysts

Jefferies highlights that the acceleration of Ebglyss is central to its positive stance and that execution risk around the product’s ramp up, including pricing, reimbursement and market adoption, remains an important factor investors must weigh.Bolsamania

Almirall’s financial calendar indicates that the next earnings update is scheduled for February 22, 2027, which will provide a clearer picture of how Ebglyss and other key assets are performing and whether the company is on track to meet its medium term guidance targets.TradingView

Almirall stock remains below analyst target

Almirall stock closed the last completed trading session at EUR 10.62 on the Spanish Mercado Continuo on September 17, 2026, leaving the shares well below the EUR 16.00 price target reiterated by Jefferies and only modestly above the 52-week low around EUR 10.02, a gap that frames the upside scenario for medium term oriented investors.

More news and analyses on Almirall stock